AstraZeneca teams up with Imperial offshoot VaxEquity on an RNA 3.0 effort
Last year, Imperial College London professor Robin Shattock was given close to $50 million by the UK government to make an RNA-based Covid-19 vaccine. While that fell through, the deal his company VaxEquity just signed with Big Pharma could be worth almost four times that amount — with increased exposure to boot.
Introduce AstraZeneca, which just signed a deal worth $195 million in milestones with Shattock’s company on a platform based on Shattock’s work on a new type of RNA as self-amplifying RNA, or saRNA. AstraZeneca and VaxEquity will collaborate on up to 26 drug targets, which remain undisclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
